AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Providing an interesting take on the pharma sector was Deutsche Bank, which Wednesday raised its target price on AstraZeneca PLC (LSE:AZN). It pointed out (rightly) that a backdrop of rising inflation wouldn't normally be a 'positive' for defensive plays such as major European drugs stocks.

Are AstraZeneca PLC shares a 'buy'? This leading bank is a fan

Campaign aims to increase understanding of the role of biomarker testing to complete a lung cancer diagnosis WASHINGTON , April 4, 2022 /PRNewswire/ -- Jason Day, pro-golfer and PGA Champion, joins AstraZeneca to launch the Getting Out of the Rough campaign, aimed to educate lung cancer patients and their caregivers about biomarker testing and the importance of completing a lung cancer diagnosis through this approach. The Getting Out of the Rough campaign features a six-episode video series, where Jason is joined by friends from the worlds of medicine and entertainment to discuss and learn about adapting after you or someone you love has been diagnosed with lung cancer.

PGA Champion Jason Day Launches Getting Out of the Rough Video Series With AstraZeneca to Support Lung Cancer Biomarker Testing Awareness

Abbott Labs

BioNTech SE

UnitedHealth Group

Valneva SE

Are these health care stocks on your watchlist right now?

5 Top Health Care Stocks To Watch In The Stock Market Today

Moderna

Pfizer

These vaccine stocks are likely to trend higher with the recent surge in covid-19 cases and concerns related to a new variant. The post 3 Vaccine Stocks to Buy on the New Covid Variant Surge appeared first on InvestorPlace.

3 Vaccine Stocks to Buy on the New Covid Variant Surge

AstraZeneca PLC (LSE:AZN) said its Ondexxya treatment was approved in Japan, the first approved reversal agent specifically for Factor Xa inhibitors in the country. Ondexxya is a modified form of the human FXa molecule, an enzyme that helps blood clots.

AstraZeneca's Ondexxya wins approval for reversal of acute major bleeds in patients

GlaxoSmithKline PLC (LON:GSK), Johnson & Johnson (FRA:JNJ), and AstraZeneca PLC (LON:AZN) are certainly the best in the big pharma industry. As the companies compete in the drug wars, investors only want to know which stock provides the best investment opportunity.

In the big pharma sector, the best buy is AstraZeneca at prices below $56

The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.

AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail

AstraZeneca PLC (LSE:AZN) has received EU marketing authorisation for its Evusheld antibody combination for the prevention of COVID-19 in a broad population. The Cambridge, England-based firm said the drug was approved for the prevention of COVID-19 in people aged 12 years and older who weigh at least 40 kilograms.

AstraZeneca's COVID drug bags EU approval

Nuformix PLC (LSE:NFX) said its patent application for key asset NXP004 had progressed to the publication phase. Following this, it was able to reveal that NXP004 is a novel, or new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers.

Nuformix says patent application for reformulated AstraZeneca blockbuster has progressed to publication phase

AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in cervical cancer patients during a late-stage study.

AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study

Lloyds Banking Group

Lloyds Bank, AstraZeneca and Unilever are apparently three of the ways you can become an ISA millionaire, according to the latest study of the portfolios of its customers by Hargreaves Lansdown. The number of ISA millionaires on its books has jumped by two-thirds to 973, while overall there are now 2,000 in the £1mln club, said the wealth platform.

ISA millionaires up by two-thirds and by investing in Lloyds Bank and AstraZeneca

Intuitive Surgical

Teladoc

A couple of these stocks have been down big this year and could be overdue for a rally.

3 Top Healthcare Stocks to Buy for the Long Haul

AstraZeneca possesses a stacked, commercialized drug portfolio. And its pipeline of drug candidates is just as enviable.

Should You Buy This Big Pharma Stock?

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has partnered with The National Fish and Wildlife Foundation (NFWF) to plant and sustain one million trees in the United States by the end of 2025. This initiative is part of the Company's flagship Ambition Zero Carbon program to decarbonize its global operations by eliminating, reducing and substituting for our greenhouse gas emissions, and become carbon negative across our value chain by 2030, in line with science-based targets. As part of its su

AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees

AstraZeneca PLC (LSE:AZN) said an advanced-stage study of its Imfinzi drug failed to meets its target of improving survival in patients with cervical cancer. The CALLA phase 3 trial of Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint to improve progression-free survival in patients with locally advanced cervical cancer when used concurrently with chemoradiotherapy (CRT), compared with the use of CRT alone, the pharmaceutical firm said in a statement.

AstraZeneca's Imfinzi fails to meet primary endpoint in phase 3 cervical cancer trial

AstraZeneca has taken a roughly £25 million ($33 million) stake in U.K. health start-up Huma, according to a person familiar with the matter.

AstraZeneca takes stake in a start-up that helps doctors conduct clinical trials virtually

A small AstraZeneca ( AZN , Financial) spinoff that was struggling has been revived thanks to what it thinks could become a billion-dollar drug.

Liver Drug Saves AstraZeneca Spinoff

Regeneron Pharmaceuticals

Revance Therapeutics

Should you be paying attention to these biotech stocks right now?

3 Top Biotech Stocks To Watch This Week

AstraZeneca PLC (LSE:AZN) is ready to drop attempts to get its Covid-19 vaccine approved in the US, according to reports last night. Sir Mene Pangalos, AstraZeneca's head of research and development, told the FT that the company did not need to "push in places we are not needed or wanted".

AstraZeneca ready to drop US approval attempt for Covid vaccine - report

Merck

Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death

AstraZeneca PLC (LSE:AZN)'s preventative treatment for COVID-19 has been approved by the UK medical regulator, as an alternative for people for whom vaccines are not effective. The new medicine, Evusheld, is a combination of two long-acting human monoclonal antibodies, tixagevimab and cilgavimab, has been authorised for COVID-19 prevention by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

AstraZeneca's COVID vaccine alternative gets UK green light

Alexion Pharma

AstraZeneca PLC (LSE:AZN) is set to pay out US$775mln to settle a patent dispute between its recently acquired rare diseases business Alexion and the Chugai Pharmaceutical Company. The litigation relates to a drug called Ultomiris, used to treat paroxysmal nocturnal hemoglobinuria and atypical haemolytic uraemic syndrome – two life-threatening conditions.

AstraZeneca to pay US$775mln to settle Alexion patent dispute

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced further positive results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who

LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer

AstraZeneca PLC (LSE:AZN)'s application for Evusheld, an antibody-based Coronavirus (COVID-19) therapy is being reviewed by the European Medicines Agency, in an important step towards approval by the region. The EMA's Committee for Medicinal Products for Human Use (CHMP) has, however, not set a deadline for concluding the review, a Reuters report said, citing the drug regulator.

AstraZeneca's COVID-19 drug application under review by EU regulators

LumiraDx Ltd

Could health care stocks be the top picks in the stock market this week?

News for AstraZeneca Stock (AZN)